Legend Biotech Corporation
Legend Biotech Corporation (LEGN) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Legend Biotech Corporation (LEGN), featuring income statements, balance sheets, and cash flow data.
Legend Biotech Corporation (LEGN) Income Statement & Financial Overview
Review Legend Biotech Corporation LEGN income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $186.52M | $160.21M | $186.52M | $93.99M |
| Cost of Revenue | $73.92M | $55.47M | $50.45M | $60.46M |
| Gross Profit | $112.60M | $104.74M | $136.07M | $33.53M |
| Gross Profit Ratio | $0.60 | $0.65 | $0.73 | $0.36 |
| R&D Expenses | $104.43M | $95.52M | $112.63M | $100.96M |
| SG&A Expenses | $83.13M | $79.57M | $65.42M | $50.43M |
| Operating Expenses | $187.00M | $104.74M | $178.04M | $151.39M |
| Total Costs & Expenses | $260.92M | $160.21M | $228.49M | $211.85M |
| Interest Income | $13.65M | $16.63M | $17.05M | $13.87M |
| Interest Expense | $5.15M | $5.50M | $5.48M | $5.47M |
| Depreciation & Amortization | $6.80M | $5.47M | $5.37M | $5.72M |
| EBITDA | $52.46M | -$109.91M | -$7.12M | -$48.59M |
| EBITDA Ratio | $0.28 | -$0.69 | -$0.04 | -$0.52 |
| Operating Income | -$74.39M | $0.00 | -$41.55M | -$117.86M |
| Operating Income Ratio | -$0.40 | $0.00 | -$0.22 | -$1.25 |
| Other Income/Expenses (Net) | $114.91M | -$120.89M | $23.58M | $58.08M |
| Income Before Tax | $40.51M | -$120.89M | -$17.97M | -$59.79M |
| Income Before Tax Ratio | $0.22 | -$0.75 | -$0.10 | -$0.64 |
| Income Tax Expense | $14.23M | $4.43M | $226000.00 | $5000.00 |
| Net Income | $26.28M | -$125.32M | -$18.20M | -$59.79M |
| Net Income Ratio | $0.14 | -$0.78 | -$0.10 | -$0.64 |
| EPS | $0.28 | $0.00 | -$0.20 | -$0.66 |
| Diluted EPS | $0.28 | $0.00 | -$0.20 | -$0.66 |
| Weighted Avg Shares Outstanding | $91.43M | $0.00 | $91.30M | $91.003M |
| Weighted Avg Shares Outstanding (Diluted) | $91.43M | $0.00 | $91.30M | $91.003M |
Financial performance has remained strong, with revenue growing from $93.99M in Q1 2024 to $186.52M in Q4 2024. Gross profit continued to perform well, with margins at 60% in the latest quarter. Operating income reached -$74.39M in Q4 2024, holding a steady -40% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $52.46M. Net income rose to $26.28M, keeping EPS at $0.28. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan